蔣琦
查看科室更多醫(yī)生科 室：腫瘤內(nèi)科（一）
性 別：男
最高學(xué)歷,、學(xué)位：研究生,、碩士
職 稱：主治醫(yī)師
院內(nèi)職務(wù)：腫瘤內(nèi)科黨支部宣傳委員
個(gè)人簡介
畢業(yè)于第二軍醫(yī)大學(xué)（腫瘤學(xué)碩士），目前浙江大學(xué)腫瘤學(xué)博士在讀,，至今以第一/共同第一作者發(fā)表SCI論文10余篇,。
專業(yè)擅長
擅長肺癌、乳腺癌,、胃癌腸癌等消化道腫瘤,、泌尿系和婦科腫瘤等各類癌癥的化療、靶向治療和免疫治療,，倡導(dǎo)腫瘤患者全程管理和精準(zhǔn)治療,。
研究方向
消化道腫瘤和肺癌發(fā)病機(jī)制和臨床轉(zhuǎn)化性研究。
成果獎(jiǎng)項(xiàng)：（近五年主要成果及獎(jiǎng)勵(lì)情況）
(1) Qi Jiang#, Mixue Xie#, Ruyin Chen#, Feifei Yan, Chanqi Ye, Qiong Li, Shuaishuai Xu, Wei Wu, Yunlu Jia*, Peng Shen* Jian Ruan*; Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments, Frontiers in Immunology, 2022, 13: 973601
(2) Feifei Yan#, Qi Jiang#, Bin Ru, Xiaojie Fei, Jian Ruan, Xiaochen Zhang*; Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody: A case report, World Journal of Clinical Cases, 2022, 10(8): 2497-2503
(3) Luo Wang#, Qi Jiang#, MengYe He, Peng Shen*; HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review, World Journal of Clinical Cases, 2022, 10(1): 260-267
(4) Feifei Yan#, Qi Jiang#, Mengye He*, Peng Shen*;PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis, Future Oncology. 2021,17(18):2381-2393.
(5) Mixue Xie#; Qi Jiang#; Shuqi Zhao; Jing Zhao; Xiujin Ye*; Wenbin Qian*; Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis, International Immunopharmacology, 2020, 85:106684.
(6) Qi Jiang#; Mixue Xie#; Xiaochen Zhang*; Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report, World Journal of Clinical Cases, 2020, v.8(03):112-117.
(7) Qi Jiang#; Mixue Xie#; Mengye He; Feifei Yan; Ming Chen; Suzhen Xu; Xiaochen Zhang*; Peng Shen*; PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer, Medicine, 2019, 98:1(e13820).
(8) Qi Jiang#; Peng Shen*; Assessment quality of life with hand-foot syndrome induced by apatinib combined with anti-PD-1 therapy in NSCLC, Annals of Oncology, 2019,30(sup 5).
(9) Yao Chen#, Xiaochen Zhang, Qi Jiang, BoWang, Yina Wang*, JunrongYan; Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib, Lung Cancer, 2020, 146:370-372.
(10) Mixue Xie#, Lulu Wang#, Qi Jiang, Xuxia Luo, Xin Zhao, Xueying Li, Jie Jin, Xiujin Ye*, Kui Zhao*;Signifcance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma, Cancer Cell International, 2021, 21:394.
(11) Wen Lei#, Mixue Xie#, Qi Jiang, Nengwen Xu, Ping Li, Aibin Liang, Ken H. Young, Wenbin Qian*; Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis, Cancers, 2021, 13, 3912.
(12) Suzhen Xu#, Xiaochen Zhang#, Qi Jiang, Ming Chen, Mengye He, Peng Shen*; Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report, World Journal of Clinical Cases, 2022, 10(28): 10236-10243
(13) Ruyin Chen#, Dandan Zheng#, Qiong Li#, Shuaishuai Xu, Chanqi Ye, Qi Jiang, Feifei Yan, Yunlu Jia*, Xiaochen Zhang*, Jian Ruan*; Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers, Cancer Letters, 2022, 546: 215853
(14) Qiong Li#, Chanqi Ye#, Tian Tian, Qi Jiang, Peng Zhao, Xiaoting Wang, Feiye Liu, Jianzhen Shan, Jian Ruan*; The emerging role of ubiquitin-specific protease 20 in tumorigenesis and cancer therapeutics, Cell Death and Disease, 2022, 13(5): 434
(15) Ruyin Chen#, Qiong Li#, Shuaishuai Xu#, Chanqi Ye, Tian Tian, Qi Jiang, Jianzhen Shan*, Jian Ruan*; Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment, Cancer Cell International, 2022, 22(1): 73
(16) Kaili Cen#, Ming Chen#, Mengye He#, Zhenhao Li, Yinjing Song, Pu Liu, Qi Jiang, Suzhen Xu, Yunlu Jia*, Peng Shen*; Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity, Frontiers in Pharmacology, 2022, 13: 826716
(17) Jian Ruan#, Shuaishuai Xu#, Ruyin Chen#, Wenxin Qu, Qiong Li, Chanqi Ye, Wei Wu, Qi Jiang, Feifei Yan, Enhui Shen, Qinjie Chu, Yunlu Jia, Xiaochen Zhang, Wenguang Fu, Jinzhang Chen, Michael P Timko, Peng Zhao*, Longjiang Fan*, Yifei Shen*; EMLI-ICC: an ensemble machine learning-based integration algorithm for metastasis prediction and risk stratification in intrahepatic cholangiocarcinoma, Briefings in Bioinformatics, 2022, 18: bbac450
（18）俞素芬#,唐林娜,陳佳潔,張曉琛,蔣琦*.不同量表對(duì)SHR-1210聯(lián)合阿帕替尼治療晚期非小細(xì)胞肺癌致手足綜合征患者的生活質(zhì)量評(píng)估效果比較[J].中華危重癥醫(yī)學(xué)雜志（電子版）,2020,13(4):284-287.
社會(huì)任職
浙江省抗癌協(xié)會(huì)癌痛專委會(huì) 青年委員
